Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer

To determine the efficacy and tolerability of SPI-77 (sterically stabilised liposomal cisplatin) at three dose levels in patients with advanced non-small-cell lung cancer (NSCLC). Patients had Stage IIIB or IV NSCLC and were chemo-naïve, and Eastern Oncology Cooperative Group 0–2. The first cohort r...

Descripción completa

Detalles Bibliográficos
Autores principales: White, S C, Lorigan, P, Margison, G P, Margison, J M, Martin, F, Thatcher, N, Anderson, H, Ranson, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360546/
https://www.ncbi.nlm.nih.gov/pubmed/16969346
http://dx.doi.org/10.1038/sj.bjc.6603345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360546/
https://www.ncbi.nlm.nih.gov/pubmed/16969346
http://dx.doi.org/10.1038/sj.bjc.6603345

Ejemplares similares